Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Deciphera announces Health Canada authorizes sale of Qinlock » 07:09
06/22/20
06/22
07:09
06/22/20
07:09
DCPH

Deciphera

$62.68 /

+2.475 (+4.11%)

Deciphera announced that…

Deciphera announced that Health Canada has authorized QIinlock, a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor, or GIST, who have received prior treatment with imatinib, sunitinib and regorafenib. The Qinlock new drug submission was approved by Health Canada under Project Orbis, an initiative of the FDA's Oncology Center of Excellence designed to provide a framework for concurrent submission and review of oncology products among international partners. In May, Qinlock was approved by the FDA for the treatment of adult patients with advanced GIST who have received prior treatment with three or more kinase inhibitors, including imatinib. Health Canada's authorization was based on efficacy results from the pivotal Phase 3 INVICTUS study of Qinlock in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of Qinlock. In INVICTUS, Qinlock demonstrated a median progression-free survival of 6.3 months compared to one month in the placebo arm and significantly reduced the risk of disease progression or death by 85%. In addition, Qinlock demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64%. The most common adverse reactions were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome, or PPES, and vomiting. Adverse reactions resulting in permanent discontinuation occurred in 8% of patients, dosage interruptions due to an adverse reaction occurred in 24% of patients and dose reductions due to an adverse reaction occurred in 7% of patients who received Qinlock.

ShowHide Related Items >><<
DCPH Deciphera
$62.68 /

+2.475 (+4.11%)

DCPH Deciphera
$62.68 /

+2.475 (+4.11%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
DCPH Deciphera
$62.68 /

+2.475 (+4.11%)

DCPH Deciphera
$62.68 /

+2.475 (+4.11%)

Hot Stocks
Deciphera announces INVICTUS study results published » 07:35
06/08/20
06/08
07:35
06/08/20
07:35
DCPH

Deciphera

$55.15 /

+1.495 (+2.79%)

Deciphera announced that…

Deciphera announced that The Lancet Oncology has published results from the INVICTUS pivotal Phase 3 study of Qinlock in patients with fourth-line gastrointestinal stromal tumor, or GIST. The INVICTUS study met its primary endpoint, demonstrating a statistically significantly improvement in progression free survival, or PFS, in patients randomized to Qinlock compared with patients receiving placebo. The safety profile observed in INVICTUS was consistent with previously published results, and results from the study were previously presented at the European Society of Medical Oncology Congress in September 2019. The article is now available online and will be published in a future print issue of The Lancet Oncology. Qinlock demonstrated a median PFS of 6.3 months compared to one month in the placebo arm and significantly reduced the risk of disease progression or death by 85%. Qinlock demonstrated a median overall survival of 15.1 months compared to 6.6 months in the placebo arm and reduced the risk of death by 64%. The most common adverse reactions were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome and vomiting. Adverse reactions resulting in permanent discontinuation occurred in 8% of patients, dosage interruptions due to an adverse reaction occurred in 24% of patients and dose reductions due to an adverse reaction occurred in 7% of patients who received Qinlock.

ShowHide Related Items >><<
DCPH Deciphera
$55.15 /

+1.495 (+2.79%)

DCPH Deciphera
$55.15 /

+1.495 (+2.79%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
DCPH Deciphera
$55.15 /

+1.495 (+2.79%)

DCPH Deciphera
$55.15 /

+1.495 (+2.79%)

Over a month ago
Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55
05/31/20
05/31
04:55
05/31/20
04:55
ABBV

AbbVie

$92.78 /

+2.77 (+3.08%)

, ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, ATNX

Athenex

$10.91 /

-0.21 (-1.89%)

, AVEO

Aveo Pharmaceuticals

$8.14 /

-1.08 (-11.71%)

, AZN

AstraZeneca

$54.60 /

+1.1 (+2.06%)

, BCYC

Bicycle Therapeutics

$17.50 /

-0.785 (-4.29%)

, BLUE

Bluebird Bio

$63.63 /

+2.82 (+4.64%)

, BPMC

Blueprint Medicines

$65.16 /

-1.84 (-2.75%)

, CGEN

Compugen

$15.50 /

+3.13 (+25.30%)

, HALO

Halozyme

$24.26 /

+0.79 (+3.37%)

, EXEL

Exelixis

$24.68 /

+0.35 (+1.44%)

, DCPH

Deciphera

$58.47 /

+1.53 (+2.69%)

, KURA

Kura Oncology

$17.09 /

+0.38 (+2.27%)

, KPTI

Karyopharm

$18.49 /

-0.31 (-1.65%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, BMY

Bristol-Myers

$59.72 /

-0.08 (-0.13%)

, MRSN

Mersana Therapeutics

$22.55 /

+2.85 (+14.47%)

, NXTC

NextCure

$31.20 /

-1.96 (-5.91%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.85 /

+0.3 (+1.62%)

, SBPH

Spring Bank Pharmaceuticals

$1.66 /

+0.015 (+0.91%)

, SGEN

Seattle Genetics

$157.30 /

+5.53 (+3.64%)

, STML

Stemline

$11.89 /

+ (+0.00%)

, SYRS

Syros Pharmaceuticals

$9.77 /

+0.25 (+2.63%)

, TRIL

Trillium Therapeutics

$6.76 /

+0.995 (+17.26%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.30 /

-0.69 (-2.23%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
05/29/20 Piper Sandler
Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$10.91 /

-0.21 (-1.89%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

05/29/20 Piper Sandler
Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler
05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
CGEN Compugen
$15.50 /

+3.13 (+25.30%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$24.26 /

+0.79 (+3.37%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$31.20 /

-1.96 (-5.91%)

05/29/20 Piper Sandler
NextCure data shows S15-mediated activity, says Piper Sandler
05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.89 /

+ (+0.00%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

XNCR Xencor
$30.30 /

-0.69 (-2.23%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 04:55
05/30/20
05/30
04:55
05/30/20
04:55
ABBV

AbbVie

$92.78 /

+2.77 (+3.08%)

, ALLO

Allogene Therapeutics

$48.08 /

+1.48 (+3.18%)

, AMGN

Amgen

$230.13 /

+6.11 (+2.73%)

, ATNX

Athenex

$10.91 /

-0.21 (-1.89%)

, AVEO

Aveo Pharmaceuticals

$8.14 /

-1.08 (-11.71%)

, AZN

AstraZeneca

$54.60 /

+1.1 (+2.06%)

, BCYC

Bicycle Therapeutics

$17.50 /

-0.785 (-4.29%)

, BLUE

Bluebird Bio

$63.63 /

+2.82 (+4.64%)

, BPMC

Blueprint Medicines

$65.16 /

-1.84 (-2.75%)

, CGEN

Compugen

$15.50 /

+3.13 (+25.30%)

, HALO

Halozyme

$24.26 /

+0.79 (+3.37%)

, EXEL

Exelixis

$24.68 /

+0.35 (+1.44%)

, DCPH

Deciphera

$58.47 /

+1.53 (+2.69%)

, KURA

Kura Oncology

$17.09 /

+0.38 (+2.27%)

, KPTI

Karyopharm

$18.49 /

-0.31 (-1.65%)

, MRK

Merck

$80.85 /

+1.83 (+2.32%)

, BMY

Bristol-Myers

$59.72 /

-0.08 (-0.13%)

, MRSN

Mersana Therapeutics

$22.55 /

+2.85 (+14.47%)

, NXTC

NextCure

$31.20 /

-1.96 (-5.91%)

, PFE

Pfizer

$38.14 /

-0.03 (-0.08%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.85 /

+0.3 (+1.62%)

, SBPH

Spring Bank Pharmaceuticals

$1.66 /

+0.015 (+0.91%)

, SGEN

Seattle Genetics

$157.30 /

+5.53 (+3.64%)

, STML

Stemline

$11.89 /

+ (+0.00%)

, SYRS

Syros Pharmaceuticals

$9.77 /

+0.25 (+2.63%)

, TRIL

Trillium Therapeutics

$6.76 /

+0.995 (+17.26%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.30 /

-0.69 (-2.23%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

05/29/20 H.C. Wainwright
Allogene Therapeutics price target raised to $55 from $42 at H.C. Wainwright
05/29/20 Piper Sandler
Allogene Therapeutics price target raised to $70 from $50 at Piper Sandler
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
AMGN Amgen
$230.13 /

+6.11 (+2.73%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$10.91 /

-0.21 (-1.89%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

05/29/20 Piper Sandler
Aveo Pharmaceuticals price target raised to $26 from $18.50 at Piper Sandler
05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
CGEN Compugen
$15.50 /

+3.13 (+25.30%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$24.26 /

+0.79 (+3.37%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

05/29/20 Piper Sandler
Kura's tipifarnib updates support tumor agnostic potential, says Piper Sandler
05/29/20 H.C. Wainwright
Kura data 'solidifying' confidence in AIM-HN study, says H.C. Wainwright
05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$80.85 /

+1.83 (+2.32%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$31.20 /

-1.96 (-5.91%)

05/29/20 Piper Sandler
NextCure data shows S15-mediated activity, says Piper Sandler
05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
PFE Pfizer
$38.14 /

-0.03 (-0.08%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.89 /

+ (+0.00%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

05/29/20 Roth Capital
Syros Pharmaceuticals ASCO update bodes well for ph1 data, says Roth Capital
05/29/20 Piper Sandler
Syros price target raised to $14 after ASCO update at Piper Sandler
04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.30 /

-0.69 (-2.23%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

SYRS Syros Pharmaceuticals
$9.77 /

+0.25 (+2.63%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

REPL Replimune Group
$18.85 /

+0.3 (+1.62%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

NXTC NextCure
$31.20 /

-1.96 (-5.91%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KURA Kura Oncology
$17.09 /

+0.38 (+2.27%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

CGEN Compugen
$15.50 /

+3.13 (+25.30%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

  • 29
    May
TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

XNCR Xencor
$30.30 /

-0.69 (-2.23%)

STML Stemline
$11.89 /

+ (+0.00%)

SGEN Seattle Genetics
$157.30 /

+5.53 (+3.64%)

SBPH Spring Bank Pharmaceuticals
$1.66 /

+0.015 (+0.91%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

KPTI Karyopharm
$18.49 /

-0.31 (-1.65%)

HALO Halozyme
$24.26 /

+0.79 (+3.37%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

DCPH Deciphera
$58.47 /

+1.53 (+2.69%)

BPMC Blueprint Medicines
$65.16 /

-1.84 (-2.75%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

BLUE Bluebird Bio
$63.63 /

+2.82 (+4.64%)

BCYC Bicycle Therapeutics
$17.50 /

-0.785 (-4.29%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

AVEO Aveo Pharmaceuticals
$8.14 /

-1.08 (-11.71%)

ATNX Athenex
$10.91 /

-0.21 (-1.89%)

AMGN Amgen
$230.13 /

+6.11 (+2.73%)

ALLO Allogene Therapeutics
$48.08 /

+1.48 (+3.18%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

TRIL Trillium Therapeutics
$6.76 /

+0.995 (+17.26%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.14 /

-0.03 (-0.08%)

MRSN Mersana Therapeutics
$22.55 /

+2.85 (+14.47%)

MRK Merck
$80.85 /

+1.83 (+2.32%)

EXEL Exelixis
$24.68 /

+0.35 (+1.44%)

BMY Bristol-Myers
$59.72 /

-0.08 (-0.13%)

AZN AstraZeneca
$54.60 /

+1.1 (+2.06%)

ABBV AbbVie
$92.78 /

+2.77 (+3.08%)

Conference/Events
American Society of Clinical Oncology (ASCO) to hold virtual meeting » 10:14
05/29/20
05/29
10:14
05/29/20
10:14
ABBV

AbbVie

$90.97 /

+0.96 (+1.07%)

, ALLO

Allogene Therapeutics

$45.80 /

-0.8 (-1.72%)

, AMGN

Amgen

$224.10 /

+0.08 (+0.04%)

, ATNX

Athenex

$11.08 /

-0.04 (-0.36%)

, AVEO

Aveo Pharmaceuticals

$8.01 /

-1.21 (-13.12%)

, AZN

AstraZeneca

$54.97 /

+1.47 (+2.75%)

, BCYC

Bicycle Therapeutics

$18.28 /

+ (+0.00%)

, BLUE

Bluebird Bio

$61.30 /

+0.49 (+0.81%)

, BPMC

Blueprint Medicines

$66.44 /

-0.56 (-0.84%)

, CGEN

Compugen

$12.92 /

+0.55 (+4.45%)

, HALO

Halozyme

$23.49 /

+0.02 (+0.09%)

, EXEL

Exelixis

$24.46 /

+0.13 (+0.53%)

, DCPH

Deciphera

$56.95 /

+0.01 (+0.02%)

, KURA

Kura Oncology

$17.10 /

+0.39 (+2.33%)

, KPTI

Karyopharm

$18.80 /

+ (+0.00%)

, MRK

Merck

$79.24 /

+0.22 (+0.28%)

, BMY

Bristol-Myers

$60.18 /

+0.38 (+0.64%)

, MRSN

Mersana Therapeutics

$20.50 /

+0.8 (+4.06%)

, NXTC

NextCure

$32.56 /

-0.6 (-1.81%)

, PFE

Pfizer

$38.06 /

-0.11 (-0.29%)

, RECN

Changed to RGP

$0.00 /

+ (+0.00%)

, REPL

Replimune Group

$18.41 /

-0.14 (-0.75%)

, SBPH

Spring Bank Pharmaceuticals

$1.56 /

-0.085 (-5.17%)

, SGEN

Seattle Genetics

$154.34 /

+2.57 (+1.69%)

, STML

Stemline

$11.88 /

-0.01 (-0.08%)

, SYRS

Syros Pharmaceuticals

$9.43 /

-0.09 (-0.95%)

, TRIL

Trillium Therapeutics

$6.20 /

+0.435 (+7.55%)

, TROV

Changed name to CRDF

$0.00 /

+ (+0.00%)

, XNCR

Xencor

$30.45 /

-0.54 (-1.74%)

Virtual Annual Meeting of…

Virtual Annual Meeting of ASCO 2020 will be held on May 29-31. Webcast Link

ShowHide Related Items >><<
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

NXTC NextCure
$32.56 /

-0.6 (-1.81%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

CGEN Compugen
$12.92 /

+0.55 (+4.45%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

05/22/20 Piper Sandler
Growth of Biohaven's Nurtec continues to beat AbbVie's Ubrelvy, says Piper
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
05/18/20 BofA
AbbVie reinstated with a Neutral at BofA
05/12/20 JPMorgan
AbbVie resumed with an Overweight from Neutral at JPMorgan
ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy with $60 target at Roth Capital
05/19/20 Roth Capital
Allogene Therapeutics upgraded to Buy from Neutral at Roth Capital
05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
05/15/20 Guggenheim
Guggenheim upgrades Allogene to Buy with $50 target after ASCO upside surprise
AMGN Amgen
$224.10 /

+0.08 (+0.04%)

05/28/20 Piper Sandler
Alexion settlement could 'clear the deck' for acquirer, says Piper Sandler
05/28/20 Cowen
Alexion settlement may yield upside surprise, says Cowen
05/28/20 Stifel
Alexion, Amgen appear to have agreed to settlement deal, says Stifel
05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
ATNX Athenex
$11.08 /

-0.04 (-0.36%)

12/13/19 RBC Capital
Athenex oraxol OS and ORR a 'best case,' buy on weakness, says RBC Capital
12/06/19 SunTrust
Athenex initiated with a Buy at SunTrust
11/19/19 RBC Capital
Athenex gets 'third SABCS win' ahead of meeting, says RBC Capital
08/07/19 RBC Capital
Athenex's Oraxol data 'near best-case,' says RBC Capital
AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

05/29/20 Baird
Aveo Pharmaceuticals price target raised to $24 from $15 at Baird
05/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $10 from $6 at H.C. Wainwright
04/01/20 H.C. Wainwright
Aveo Pharmaceuticals price target raised to $6 from $4 at H.C. Wainwright
03/31/20 Piper Sandler
Aveo Pharmaceuticals price target lowered to $18.50 from $20 at Piper Sandler
AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

05/29/20 Guggenheim
AstraZeneca price target raised to 10,100 GBp from 9,100 GBp at Guggenheim
05/14/20 Evercore ISI
Evercore ISI says paper 'generally supportive' of AstraZeneca COVID vaccine
05/06/20 Morgan Stanley
AstraZeneca price target raised to 8,630 GBp from 8,600 GBp at Morgan Stanley
05/04/20 Citi
Citi opens 'positive catalyst watch' on AstraZeneca
BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

04/17/20
Fly Intel: Top five analyst initiations
04/17/20 H.C. Wainwright
Bicycle Therapeutics initiated with a Buy at H.C. Wainwright
04/07/20 Piper Sandler
Bicycle Therapeutics' timelines to be impacted by COVID-19, says Piper Sandler
02/25/20 Piper Sandler
Bicycle Therapeutics price target raised to $30 from $20 at Piper Sandler
BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

05/13/20 Stifel
Bluebird's ide-cel remains approvable despite FDA's 'strict stance,' says Stifel
05/13/20 Piper Sandler
Bluebird should be able to easily address RTF issues, says Piper Sandler
05/12/20 RBC Capital
Bluebird Bio initiated with an Outperform at RBC Capital
05/12/20 Oppenheimer
Bluebird Bio price target lowered to $111 from $122 at Oppenheimer
BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
CGEN Compugen
$12.92 /

+0.55 (+4.45%)

05/26/20 JMP Securities
Compugen resumed with an Outperform at JMP Securities
05/13/20
Fly Intel: Top five analyst initiations
05/13/20 Stifel
Compugen initiated with a Buy at Stifel
05/07/20
Fly Intel: Top five analyst initiations
HALO Halozyme
$23.49 /

+0.02 (+0.09%)

05/26/20 Piper Sandler
Halozyme's Enhanze business nearing accelerated growth, says Piper Sandler
05/12/20 JMP Securities
Halozyme price target raised to $34 from $24 at JMP Securities
05/04/20 Cantor Fitzgerald
Halozyme price target raised to $39 from $35 at Cantor Fitzgerald
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

05/14/20 SunTrust
Exelixis price target raised to $40 from $35 at SunTrust
05/13/20 Piper Sandler
Exelixis mCRPC data for CABOMETYX may accelerate approval, says Piper Sandler
05/06/20 Piper Sandler
Exelixis price target raised to $30 from $23 at Piper Sandler
04/21/20 Guggenheim
Exelixis price target raised to $32 from $27 at Guggenheim
DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

05/19/20 Deutsche Bank
Kura Oncology price target lowered to $24 from $28 at Deutsche Bank
05/06/20 Wedbush
Kura prioritizing development of tipifarnib for HRAS-HNSCC, says Wedbush
05/05/20 H.C. Wainwright
Kura Oncology price target lowered to $22 from $29 at H.C. Wainwright
05/05/20 Barclays
Kura Oncology initiated with an Overweight at Barclays
KPTI Karyopharm
$18.80 /

+ (+0.00%)

05/06/20 H.C. Wainwright
Karyopharm price target lowered to $40 from $43 at H.C. Wainwright
04/07/20 Wedbush
Wedbush sees signs of 'potential utility' for Karyopharm's selinexor for COVID
04/07/20 H.C. Wainwright
XPO1 inhibitors have shown promise as COVID-19 treatment, says H.C. Wainwright
03/04/20 Barclays
Karyopharm initiated with an Overweight at Barclays
MRK Merck
$79.24 /

+0.22 (+0.28%)

05/27/20 Alliance Global Partners
PDS Biotechnology initiated with a Buy at Alliance Global Partners
05/20/20 JonesTrading
Merck collaboration positions Surface Oncology well, says JonesTrading
04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

04/20/20 Piper Sandler
Exelixis combo approval would increase kidney cancer use, says Piper Sandler
MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

05/27/20 H.C. Wainwright
Mersana Therapeutics price target raised to $26 from $13 at H.C. Wainwright
04/29/20 BTIG
Mersana Therapeutics initiated with a Buy at BTIG
01/21/20 H.C. Wainwright
Mersana Therapeutics price target raised to $12 from $7 at H.C. Wainwright
08/20/19 H.C. Wainwright
H.C. Wainwright says trial initiation at higher dosing 'bodes well' for Mersana
NXTC NextCure
$32.56 /

-0.6 (-1.81%)

05/26/20 JMP Securities
NextCure initiated with an Outperform at JMP Securities
04/13/20 Piper Sandler
NextCure could report Phase I biomarker data at ASCO, says Piper Sandler
03/24/20 Benchmark
NextCure initiated with a Buy at Benchmark
03/02/20 Roth Capital
NextCure initiated with a Buy at Roth Capital
PFE Pfizer
$38.06 /

-0.11 (-0.29%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/19/20 H.C. Wainwright
BioNTech upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Goldman Sachs
After Pfizer data, Goldman says Sarepta remains 'leader' in DMD gene therapy
05/15/20 JPMorgan
JPMorgan still sees Sarepta in pole position in DMD space
RECN Changed to RGP
$0.00 /

+ (+0.00%)

01/03/20 Baird
Resources Connection Q3 guidance 'materially below' expectations, says Baird
10/03/19 JPMorgan
Resources Connection near-term outlook remains challenged, says JPMorgan
REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

05/05/20 Barclays
Replimune Group initiated with an Overweight at Barclays
03/25/20 Wedbush
Replimune Group added to Best Ideas List at Wedbush
11/11/19 Roth Capital
Replimune Group price target raised to $30 from $20 at Roth Capital
09/04/19 Roth Capital
Replimune Group initiated with a Buy at Roth Capital
SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

04/02/20 Piper Sandler
Piper Sandler keeps Neutral on Spring Bank as study enrollment expected to slow
01/29/20 Jefferies
Spring Bank Pharmaceuticals downgraded to Hold from Buy at Jefferies
01/29/20 Piper Sandler
Piper keeps Neutral rating on Spring Bank after inarigivir discontinued
12/30/19
Fly Intel: Top five analyst actions
SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 JMP Securities
Seattle Genetics initiated with an Outperform at JMP Securities
05/26/20 Goldman Sachs
Incyte downgraded to Buy from Conviction Buy at Goldman Sachs
05/26/20 Goldman Sachs
Seattle Genetics upgraded to Conviction Buy from Buy at Goldman Sachs
STML Stemline
$11.88 /

-0.01 (-0.08%)

05/05/20 H.C. Wainwright
Stemline downgraded to Neutral from Buy at H.C. Wainwright
05/05/20 Ladenburg
Stemline downgraded to Neutral from Buy at Ladenburg
05/04/20 Alliance Global Partners
Stemline downgraded to Neutral from Buy at Alliance Global Partners
05/04/20 Wedbush
Stemline downgraded to Neutral from Outperform at Wedbush
SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

04/23/20 JonesTrading
Syros Pharmaceuticals initiated with a Buy at JonesTrading
03/06/20 H.C. Wainwright
Syros Pharmaceuticals price target lowered to $8 from $10 at H.C. Wainwright
01/17/20 Wedbush
Syros Pharmaceuticals risk/reward balanced ahead of data readouts, says Wedbush
01/17/20 Wedbush
Syros Pharmaceuticals downgraded to Neutral from Outperform at Wedbush
TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

05/26/20 JMP Securities
Trillium Therapeutics initiated with an Outperform at JMP Securities
08/19/19
Fly Intel: Top five analyst downgrades
08/19/19 H.C. Wainwright
Trillium Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
TROV Changed name to CRDF
$0.00 /

+ (+0.00%)

01/28/20 Noble Capital
Trovagene resumed with an Outperform at Noble Capital
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

05/13/20 Piper Sandler
Xencor's XmAb20717 shows first-ever clinical benefit, says Piper Sandler
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Xencor initiated with an Underweight at Barclays
02/25/20 Guggenheim
Xencor upgraded to Buy from Neutral at Guggenheim
XNCR Xencor
$30.45 /

-0.54 (-1.74%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

SYRS Syros Pharmaceuticals
$9.43 /

-0.09 (-0.95%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

REPL Replimune Group
$18.41 /

-0.14 (-0.75%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

NXTC NextCure
$32.56 /

-0.6 (-1.81%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KURA Kura Oncology
$17.10 /

+0.39 (+2.33%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

CGEN Compugen
$12.92 /

+0.55 (+4.45%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

  • 29
    May
TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

XNCR Xencor
$30.45 /

-0.54 (-1.74%)

STML Stemline
$11.88 /

-0.01 (-0.08%)

SGEN Seattle Genetics
$154.34 /

+2.57 (+1.69%)

SBPH Spring Bank Pharmaceuticals
$1.56 /

-0.085 (-5.17%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

KPTI Karyopharm
$18.80 /

+ (+0.00%)

HALO Halozyme
$23.49 /

+0.02 (+0.09%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

DCPH Deciphera
$56.95 /

+0.01 (+0.02%)

BPMC Blueprint Medicines
$66.44 /

-0.56 (-0.84%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

BLUE Bluebird Bio
$61.30 /

+0.49 (+0.81%)

BCYC Bicycle Therapeutics
$18.28 /

+ (+0.00%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

AVEO Aveo Pharmaceuticals
$8.01 /

-1.21 (-13.12%)

ATNX Athenex
$11.08 /

-0.04 (-0.36%)

AMGN Amgen
$224.10 /

+0.08 (+0.04%)

ALLO Allogene Therapeutics
$45.80 /

-0.8 (-1.72%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

TRIL Trillium Therapeutics
$6.20 /

+0.435 (+7.55%)

RECN Changed to RGP
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.06 /

-0.11 (-0.29%)

MRSN Mersana Therapeutics
$20.50 /

+0.8 (+4.06%)

MRK Merck
$79.24 /

+0.22 (+0.28%)

EXEL Exelixis
$24.46 /

+0.13 (+0.53%)

BMY Bristol-Myers
$60.18 /

+0.38 (+0.64%)

AZN AstraZeneca
$54.97 /

+1.47 (+2.75%)

ABBV AbbVie
$90.97 /

+0.96 (+1.07%)

Hot Stocks
Deciphera presents results from INVICTUS pivotal Phase 3 study at ASCO » 08:24
05/29/20
05/29
08:24
05/29/20
08:24
DCPH

Deciphera

$56.94 /

-1.77 (-3.01%)

Deciphera Pharmaceuticals…

Deciphera Pharmaceuticals announced the presentation of quality of life and certain safety results from the INVICTUS pivotal Phase 3 study evaluating QINLOCK in adult patients with fourth-line advanced gastrointestinal stromal tumor, or GIST. These results were presented as part of the American Society of Clinical Oncology, or ASCO, 2020 Virtual Scientific Program. "The recent FDA approval of QINLOCK marked an important milestone for the entire GIST patient community who had been waiting for a new treatment option designed specifically for their disease," said Matthew Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera. "In addition to the impressive efficacy results shown in the INVICTUS Phase 3 study, QINLOCK was shown to have a favorable safety profile. Today's ASCO presentations demonstrate that patients receiving QINLOCK rated their overall health, quality of life, and physical and role function as better than that of patients receiving placebo. These insights into the GIST patient experience are invaluable to us as we establish a new standard of care in this area of unmet medical need."

ShowHide Related Items >><<
DCPH Deciphera
$56.94 /

-1.77 (-3.01%)

DCPH Deciphera
$56.94 /

-1.77 (-3.01%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
DCPH Deciphera
$56.94 /

-1.77 (-3.01%)

DCPH Deciphera
$56.94 /

-1.77 (-3.01%)

Hot Stocks
Deciphera presents data from cohort of Part 2 of rebastinib Phase 1b/2 at ASCO » 08:23
05/29/20
05/29
08:23
05/29/20
08:23
DCPH

Deciphera

$56.94 /

-1.77 (-3.01%)

Deciphera Pharmaceuticals…

Deciphera Pharmaceuticals announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2 clinical trial of rebastinib, the Company's investigational orally administered, potent and selective inhibitor of the TIE-2 kinase, in combination with paclitaxel. Deciphera said in a release, "The presentation, titled "An open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel in a dose expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer," will be featured during a poster session at the American Society of Clinical Oncology, or ASCO, 2020 Virtual Scientific Program. The Phase 1b/2 study of rebastinib in combination with paclitaxel is a two-part, open-label, multicenter study assessing the safety, tolerability, anti-tumor activity and pharmacokinetics of rebastinib in patients with advanced or metastatic solid tumors. Data previously presented from Part 1 of the study demonstrated encouraging preliminary anti-tumor activity, with objective responses seen across a heavily pre-treated patient population, including patients with prior exposure to paclitaxel. As previously announced, both the endometrial and ovarian cancer cohorts in Part 2 of the study advanced into the second stage of the Simon two-stage design based on demonstrating at least five responses in each cohort."

ShowHide Related Items >><<
DCPH Deciphera
$56.94 /

-1.77 (-3.01%)

DCPH Deciphera
$56.94 /

-1.77 (-3.01%)

05/18/20 SunTrust
Deciphera price target raised to $91 from $82 at SunTrust
05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
DCPH Deciphera
$56.94 /

-1.77 (-3.01%)

DCPH Deciphera
$56.94 /

-1.77 (-3.01%)

Recommendations
Deciphera price target raised to $91 from $82 at SunTrust » 08:25
05/18/20
05/18
08:25
05/18/20
08:25
DCPH

Deciphera

$51.09 /

+2.6 (+5.36%)

SunTrust analyst Robyn…

SunTrust analyst Robyn Karnauskas raised the firm's price target on Deciphera to $91 from $82 and keeps a Buy rating on the shares after the company received FDA approval for Qinlock in fourth line advanced gastrointestinal stromal tumors, noting that the WAC price for the treatment is at $32K vs. her prior estimate of $28k. The analyst further states that the company is well-funded into the second half of 2022 with several pipeline assets progressing.

ShowHide Related Items >><<
DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

05/18/20 Barclays
Deciphera price target raised to $85 from $80 at Barclays
05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

Recommendations
Deciphera price target raised to $85 from $80 at Barclays » 06:21
05/18/20
05/18
06:21
05/18/20
06:21
DCPH

Deciphera

$51.09 /

+2.6 (+5.36%)

Barclays analyst Peter…

Barclays analyst Peter Lawson raised the firm's price target on Deciphera Pharmaceuticals to $85 from $80 and keeps an Overweight rating on the shares after the company received FDA approval for Qinlock in fourth line advanced gastrointestinal stromal tumors. The analyst is encouraged by the overall survival curve included the label.

ShowHide Related Items >><<
DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

05/18/20 Piper Sandler
Piper Sandler a buyer of Deciphera shares on the open
05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral from Buy at Nomura Instinet
DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

Recommendations
Piper Sandler a buyer of Deciphera shares on the open » 05:12
05/18/20
05/18
05:12
05/18/20
05:12
DCPH

Deciphera

$51.09 /

+2.6 (+5.36%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond is a buyer of Deciphera Pharmaceuticals on today's open. The analyst anticipates "meaningful upside in coming months as the setup for the launch of Qinlock remains quite positive." The label brings few barriers to immediate uptake in the labeled fourth line advanced gastrointestinal stromal tumor setting, but meaningful off label use in earlier lines is likely well before INTRIGUE reads out next year, Raymond tells investors in a research note. The analyst keeps an Overweight rating on Deciphera with a $75 price target.

ShowHide Related Items >><<
DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

05/15/20 Piper Sandler
Deciphera's Ripretinib approved 3 months ahead of schedule, says Piper Sandler
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/06/20 Nomura Instinet
Deciphera downgraded to Neutral from Buy at Nomura Instinet
05/06/20 H.C. Wainwright
Deciphera price target raised to $80 from $60 at H.C. Wainwright
DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

DCPH Deciphera
$51.09 /

+2.6 (+5.36%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.